Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
EOLS Evolus Inc
- Stocks
- Healthcare
- NASDAQ: EOLS
Price (delayed)
$9.9
Market cap
$638.31M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.88
Enterprise value
$700.62M
Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only
Highlights
EOLS's gross profit is up by 26% year-on-year and by 3% since the previous quarter
Evolus's revenue has increased by 25% YoY and by 3.5% QoQ
The company's EPS rose by 15% YoY but it fell by 9% QoQ
Evolus's net income has decreased by 11% QoQ but it has increased by 6% YoY
Evolus's equity has shrunk by 136% YoY
The quick ratio has declined by 27% year-on-year and by 4.2% since the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.evolus.com
Key stats
What are the main financial stats of EOLS
Market
Valuations
Earnings
Shares outstanding
64.48M
Market cap
$638.31M
Enterprise value
$700.62M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
2.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.54
Revenue
$275.46M
Gross profit
$187.69M
Operating income
-$40.66M
Net income
-$56.2M
EBIT
-$37.07M
EBITDA
-$30.78M
Free cash flow
-$28.9M
Per share
Balance sheet
Liquidity
EPS
-$0.88
EPS diluted
-$0.88
Free cash flow per share
-$0.45
Book value per share
-$0.1
Revenue per share
$4.32
TBVPS
$2.24
Total assets
$213.36M
Total liabilities
$219.97M
Debt
$130.2M
Equity
-$6.6M
Working capital
$75.49M
Debt to equity
-19.72
Current ratio
2.34
Quick ratio
2.05
Net debt/EBITDA
-2.02
Margins
Efficiency
Dividend
EBITDA margin
-11.2%
Gross margin
68.1%
Net margin
-20.4%
Operating margin
-14.8%
Return on assets
-24.7%
Return on equity
-932%
Return on invested capital
-25.4%
Return on capital employed
-23.6%
Return on sales
-13.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EOLS stock price
How has the Evolus stock price performed over time
Intraday
2.06%
1 week
-0.8%
1 month
-8.25%
1 year
-27.15%
YTD
-10.33%
QTD
-17.71%
Financial performance
How have Evolus's revenue and profit performed over time
Revenue
$275.46M
Gross profit
$187.69M
Operating income
-$40.66M
Net income
-$56.2M
Gross margin
68.1%
Net margin
-20.4%
The company's operating margin rose by 30% YoY but it fell by 15% QoQ
EOLS's gross profit is up by 26% year-on-year and by 3% since the previous quarter
Evolus's revenue has increased by 25% YoY and by 3.5% QoQ
The net margin rose by 25% year-on-year but it has declined by 8% since the previous quarter
Price vs fundamentals
How does EOLS's price correlate with its fundamentals
Growth
What is Evolus's growth rate over time
Valuation
What is Evolus stock price valuation
P/E
N/A
P/B
N/A
P/S
2.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.54
The company's EPS rose by 15% YoY but it fell by 9% QoQ
Evolus's equity has shrunk by 136% YoY
The P/S is 40% less than the 5-year quarterly average of 3.8 and 26% less than the last 4 quarters average of 3.1
Evolus's revenue has increased by 25% YoY and by 3.5% QoQ
Efficiency
How efficient is Evolus business performance
The company's return on equity has shrunk by 127% QoQ
The company's return on sales rose by 33% YoY but it fell by 15% QoQ
The ROIC has grown by 27% YoY but it has contracted by 18% from the previous quarter
Evolus's ROA has increased by 23% YoY but it has decreased by 13% from the previous quarter
Dividends
What is EOLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EOLS.
Financial health
How did Evolus financials performed over time
The total assets is 3% less than the total liabilities
The company's current ratio fell by 27% YoY and by 2.5% QoQ
The quick ratio has declined by 27% year-on-year and by 4.2% since the previous quarter
Evolus's debt to equity has shrunk by 184% QoQ
Evolus's equity has shrunk by 136% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.